We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > datopotamab deruxtecan

News List

AZ/Daiichi Sankyo’s datopotamab deruxtecan demonstrates ‘promising’ early results in TNBC pharmatimes
May 11, 2021
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ACD) datopotamab deruxtecan has demonstrated 'promising' preliminary response and disease control in new data evaluating the therapy among patients with metastatic triple negative breast ...
AZ/Daiichi Sankyo’s antibody drug conjugates prove promising in early trials pharmatimes
January 29, 2021
AstraZeneca (AZ) and Daiichi Sankyo have posted new data from Phase I/II trials evaluating their respective antibody drug conjugates (ADCs) Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan.